June 2026
1. NASSIRI N, Gill IS
   Combined bladder-kidney transplantation: first-in-human feasibility trial.
   Lancet. 2026 Jun 23:S0140-6736(26)00718-X. doi: 10.1016/S0140-6736(26)00718.
   

   >> Share

   
   
2. THE LANCET
   The next steps for chronic kidney disease.
   Lancet. 2026;407:2345.
   

   >> Share

   
   
3. NEUEN BL, Heerspink HJL, Perkovic V, Cherney DZI, et al
   Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).
   Lancet. 2026;407:2375-2386.
   

   >> Share

   
   
4. LEES JS, Skoberne A, Zhang L, Wyatt C, et al
   Chronic kidney disease, complex conditions, and advancing therapeutics: new hope and challenges.
   Lancet. 2026 Jun 3:S0140-6736(26)00653-7. doi: 10.1016/S0140-6736(26)00653.
   

   >> Share

   
   
5. LEES JS, Zhang L, Anandh U, Kronbichler A, et al
   Advances in the diagnosis and detection of chronic kidney disease.
   Lancet. 2026 Jun 3:S0140-6736(26)00702-6. doi: 10.1016/S0140-6736(26)00702.
   

   >> Share

   
   April 2026
6. ZENG G, Bidel Z, Yang Q, Canoy D, et al
   Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.
   Lancet. 2026;407:1626-1638.
   

   >> Share

   
   
7. SUN Y, Guo X
   Cardiovascular benefit of blood-pressure lowering in chronic kidney disease.
   Lancet. 2026;407:1578-1580.
   

   >> Share

   
   November 2025
8. HERRINGTON WG, Judge PK, Grams ME, Wanner C, et al
   Chronic kidney disease.
   Lancet. 2025 Nov 25:S0140-6736(25)01942-7. doi: 10.1016/S0140-6736(25)01942.
   

   >> Share

   
   
9. THE LANCET
   Chronic kidney disease: breaking the silence.
   Lancet. 2025;406:2393.
   

   >> Share

   
   
10. HEERSPINK HJL, Cardona JF, Jolly S, Pergola PE, et al
    Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.
    Lancet. 2025 Nov 8:S0140-6736(25)02014-8. doi: 10.1016/S0140-6736(25)02014.
    

    >> Share

    
    
11. JHA V
    Augmenting nephroprotection: balcinrenone plus dapagliflozin in chronic kidney disease.
    Lancet. 2025 Nov 8:S0140-6736(25)02126-9. doi: 10.1016/S0140-6736(25)02126.
    

    >> Share

    
    
12. 
    Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Nov 7:S0140-6736(25)01853-7. doi: 10.1016/S0140-6736(25)01853.
    

    >> Share

    
    August 2025
13. PYNE L, Rossignol P, Giles C, Junek M, et al
    Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials.
    Lancet. 2025;406:811-820.
    

    >> Share

    
    
14. SOOMRO QH, Charytan DM
    Requiem for mineralocorticoid blockade in maintenance dialysis.
    Lancet. 2025;406:780-782.
    

    >> Share

    
    
15. ROSSIGNOL P, Zannad F, Massy Z, Azizi M, et al
    Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.
    Lancet. 2025;406:705-718.
    

    >> Share

    
    
16. WALSH M, Collister D, Gallagher M, Mark PB, et al
    Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial.
    Lancet. 2025;406:695-704.
    

    >> Share

    
    May 2025
17. LOU-MEDA R, Perez JB
    Reducing the burden of chronic kidney disease in the world.
    Lancet. 2025 May 9:S0140-6736(25)00548-3. doi: 10.1016/S0140-6736(25)00548.
    

    >> Share

    
    October 2024
18. RANCHIN B, Shroff R
    Haemodiafiltration improves survival in patients receiving dialysis.
    Lancet. 2024 Oct 25:S0140-6736(24)01938-X. doi: 10.1016/S0140-6736(24)01938.
    

    >> Share

    
    August 2024
19. MARECEK R, Kissling S, Teso AD, Vuignier Y, et al
    Chronic metabolic acidosis in a patient with diabetes on maintenance haemodialysis: mind the anion gap.
    Lancet. 2024;404:570-571.
    

    >> Share

    
    March 2024
20. WONG K, Pitcher D, Braddon F, Downward L, et al
    Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort.
    Lancet. 2024;403:1279-1289.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share